🟢 Veradermics is trading 8.61% up in pre-market after Phase 3 study met all endpoints

Veradermics is trading at $138.05, up 8.61% in pre-market on October 21, 2026, after its Phase 3 Study 304 met all primary and secondary endpoints.

• The company announced the results on October 19 for its oral hair-loss treatment, VDPHL01.
• Reports linked the earlier share surge to those results. The investor-relations page lists the announcement as its latest press release, and no separate October 21 company announcement was identified.